CA2725513C - Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer - Google Patents
Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer Download PDFInfo
- Publication number
- CA2725513C CA2725513C CA2725513A CA2725513A CA2725513C CA 2725513 C CA2725513 C CA 2725513C CA 2725513 A CA2725513 A CA 2725513A CA 2725513 A CA2725513 A CA 2725513A CA 2725513 C CA2725513 C CA 2725513C
- Authority
- CA
- Canada
- Prior art keywords
- nanoemulsion
- component
- perfluorcarbon
- gene
- genetic material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 62
- 230000012202 endocytosis Effects 0.000 title claims abstract description 31
- 238000012546 transfer Methods 0.000 title claims abstract description 31
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 27
- 108020004459 Small interfering RNA Proteins 0.000 claims description 57
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 20
- 230000001804 emulsifying effect Effects 0.000 claims description 19
- 102000004338 Transferrin Human genes 0.000 claims description 17
- 108090000901 Transferrin Proteins 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000012581 transferrin Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 150000003904 phospholipids Chemical class 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 9
- 150000002433 hydrophilic molecules Chemical class 0.000 claims description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 239000007795 chemical reaction product Substances 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 5
- 230000004700 cellular uptake Effects 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 108091070501 miRNA Proteins 0.000 claims description 3
- 239000002679 microRNA Substances 0.000 claims description 3
- -1 sphingomyelin Chemical compound 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229940031098 ethanolamine Drugs 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
- RVZRBWKZFJCCIB-UHFFFAOYSA-N perfluorotributylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RVZRBWKZFJCCIB-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229960001153 serine Drugs 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000002539 nanocarrier Substances 0.000 description 50
- 230000036772 blood pressure Effects 0.000 description 37
- 241001465754 Metazoa Species 0.000 description 35
- 239000000306 component Substances 0.000 description 24
- 102000004881 Angiotensinogen Human genes 0.000 description 17
- 108090001067 Angiotensinogen Proteins 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 230000004872 arterial blood pressure Effects 0.000 description 10
- 230000036760 body temperature Effects 0.000 description 10
- 239000000839 emulsion Substances 0.000 description 10
- 230000009467 reduction Effects 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- 238000010253 intravenous injection Methods 0.000 description 6
- 238000012384 transportation and delivery Methods 0.000 description 6
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 5
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 5
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 4
- 229960000830 captopril Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 210000001163 endosome Anatomy 0.000 description 4
- 230000036454 renin-angiotensin system Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102100028255 Renin Human genes 0.000 description 3
- 108090000783 Renin Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 238000002525 ultrasonication Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 2
- 229960001217 perflubron Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 2
- 230000029865 regulation of blood pressure Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 101000967589 Homo sapiens LRP2-binding protein Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 102100040470 LRP2-binding protein Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002802 cardiorespiratory effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 108010045676 holotransferrin Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000003303 reheating Methods 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08156434A EP2123256A1 (en) | 2008-05-19 | 2008-05-19 | Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer |
| EP08156434.6 | 2008-05-19 | ||
| PCT/EP2009/055779 WO2009141257A1 (en) | 2008-05-19 | 2009-05-13 | Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2725513A1 CA2725513A1 (en) | 2009-11-26 |
| CA2725513C true CA2725513C (en) | 2013-07-02 |
Family
ID=39869983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2725513A Active CA2725513C (en) | 2008-05-19 | 2009-05-13 | Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9616131B2 (enExample) |
| EP (3) | EP2123256A1 (enExample) |
| JP (1) | JP5546534B2 (enExample) |
| CN (2) | CN102847170B (enExample) |
| AU (1) | AU2009249812B2 (enExample) |
| CA (1) | CA2725513C (enExample) |
| DK (2) | DK2510921T3 (enExample) |
| ES (2) | ES2391375T3 (enExample) |
| HU (1) | HUE035320T2 (enExample) |
| IL (1) | IL209205A (enExample) |
| NZ (1) | NZ589417A (enExample) |
| PL (2) | PL2285349T3 (enExample) |
| WO (1) | WO2009141257A1 (enExample) |
| ZA (1) | ZA201008274B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2123256A1 (en) | 2008-05-19 | 2009-11-25 | Ruhr-Universität Bochum | Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer |
| CN103764169B (zh) * | 2011-03-31 | 2017-06-13 | 康斯坦策·沙费尔 | 用于非病毒转移核酸的全氟化化合物 |
| CN103251980B (zh) * | 2013-05-17 | 2014-07-02 | 中国人民解放军第四军医大学 | 全氟三丁胺与纤维蛋白水凝胶复合的神经导管制备方法 |
| CN103263695B (zh) * | 2013-05-17 | 2014-10-29 | 中国人民解放军第四军医大学 | 全氟三乙胺乳液与种子细胞复合的神经导管制备方法 |
| EP2853595A1 (en) * | 2013-09-30 | 2015-04-01 | Soluventis GmbH | NOTCH 1 specific siRNA molecules |
| EP3549609A4 (en) * | 2016-12-01 | 2020-07-29 | Saitama University | ENDOCYTOSIS ACTIVATOR FOR DRUG DELIVERY SYSTEMS |
| WO2025080939A1 (en) | 2023-10-13 | 2025-04-17 | Ultragenyx Pharmaceutical, Inc. | Compositions and methods for treating conditions associated with cartilage oligomeric matrix protein (comp) mutations |
| WO2025128853A2 (en) | 2023-12-13 | 2025-06-19 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating conditions associated with ube3a overexpression |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6050578B2 (ja) | 1981-12-25 | 1985-11-09 | 日本スチレンペ−パ−株式会社 | 合成樹脂発泡体の製造法 |
| FR2720943B1 (fr) | 1994-06-09 | 1996-08-23 | Applic Transferts Technolo | Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples. |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| EP0833608A2 (en) * | 1995-06-07 | 1998-04-08 | Alliance Pharmaceutical Corporation | Reverse fluorocarbon emulsion compositions for drug delivery |
| US5667809A (en) * | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
| JP2001002592A (ja) * | 1999-06-18 | 2001-01-09 | Dai Ichi Seiyaku Co Ltd | 遺伝子導入用組成物 |
| KR20080046750A (ko) | 2000-03-24 | 2008-05-27 | 바이오스피어 메디칼 인코포레이티드 | 능동 색전화용 미소구 |
| US20020155084A1 (en) * | 2000-06-02 | 2002-10-24 | The Regents Of The University Of The Michigan | Nanoemulsion formulations |
| KR20030039363A (ko) * | 2000-07-20 | 2003-05-17 | 오뜨끄리또에 악찌오네르노에 오브셰스뜨보 나우취노-쁘로이즈보드스뜨벤나야 피르마 "뻬르프또란" | 의료용 퍼플루오르 유기화합물의 유제 및 그 제조방법 및그것을 이용한 질병 치료 및 예방방법 |
| ATE392812T1 (de) | 2001-07-10 | 2008-05-15 | Sonogene Llc | Verbesserung der transfektion von dna in die leber |
| US20040115159A1 (en) | 2002-03-29 | 2004-06-17 | Tadlock Charles C | Novel nanoemulsions |
| GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| US20070184076A1 (en) | 2006-02-07 | 2007-08-09 | Unger Evan C | Liquid-filled nanodroplets for anti-cancer therapy |
| EP1844772A1 (en) | 2006-04-06 | 2007-10-17 | Polyplus-Transfection SA | Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications |
| EP2123256A1 (en) | 2008-05-19 | 2009-11-25 | Ruhr-Universität Bochum | Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer |
-
2008
- 2008-05-19 EP EP08156434A patent/EP2123256A1/en not_active Withdrawn
-
2009
- 2009-05-13 NZ NZ589417A patent/NZ589417A/en not_active IP Right Cessation
- 2009-05-13 US US12/992,280 patent/US9616131B2/en not_active Expired - Fee Related
- 2009-05-13 DK DK12171341.6T patent/DK2510921T3/en active
- 2009-05-13 ES ES09749747T patent/ES2391375T3/es active Active
- 2009-05-13 CN CN201210345209.2A patent/CN102847170B/zh not_active Expired - Fee Related
- 2009-05-13 WO PCT/EP2009/055779 patent/WO2009141257A1/en not_active Ceased
- 2009-05-13 EP EP09749747A patent/EP2285349B1/en active Active
- 2009-05-13 HU HUE12171341A patent/HUE035320T2/en unknown
- 2009-05-13 DK DK09749747.3T patent/DK2285349T3/da active
- 2009-05-13 AU AU2009249812A patent/AU2009249812B2/en not_active Ceased
- 2009-05-13 PL PL09749747T patent/PL2285349T3/pl unknown
- 2009-05-13 ES ES12171341.6T patent/ES2642316T3/es active Active
- 2009-05-13 PL PL12171341T patent/PL2510921T3/pl unknown
- 2009-05-13 JP JP2011509929A patent/JP5546534B2/ja not_active Expired - Fee Related
- 2009-05-13 CA CA2725513A patent/CA2725513C/en active Active
- 2009-05-13 EP EP12171341.6A patent/EP2510921B1/en active Active
- 2009-05-13 CN CN200980118149.7A patent/CN102112109B/zh not_active Expired - Fee Related
-
2010
- 2010-11-09 IL IL209205A patent/IL209205A/en active IP Right Grant
- 2010-11-18 ZA ZA2010/08274A patent/ZA201008274B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009249812B2 (en) | 2013-08-22 |
| CN102112109B (zh) | 2016-10-12 |
| CN102847170B (zh) | 2016-03-16 |
| EP2510921B1 (en) | 2017-07-12 |
| HK1159479A1 (zh) | 2012-08-03 |
| DK2285349T3 (da) | 2012-10-22 |
| CN102847170A (zh) | 2013-01-02 |
| EP2285349A1 (en) | 2011-02-23 |
| WO2009141257A1 (en) | 2009-11-26 |
| US9616131B2 (en) | 2017-04-11 |
| PL2285349T3 (pl) | 2012-12-31 |
| DK2510921T3 (en) | 2017-10-23 |
| CN102112109A (zh) | 2011-06-29 |
| AU2009249812A1 (en) | 2009-11-26 |
| EP2510921A1 (en) | 2012-10-17 |
| NZ589417A (en) | 2012-03-30 |
| HK1179533A1 (zh) | 2013-10-04 |
| IL209205A (en) | 2015-08-31 |
| ES2391375T3 (es) | 2012-11-23 |
| CA2725513A1 (en) | 2009-11-26 |
| HUE035320T2 (en) | 2018-05-02 |
| EP2123256A1 (en) | 2009-11-25 |
| EP2285349B1 (en) | 2012-07-11 |
| IL209205A0 (en) | 2011-01-31 |
| ES2642316T3 (es) | 2017-11-16 |
| JP2011520936A (ja) | 2011-07-21 |
| US20110091561A1 (en) | 2011-04-21 |
| JP5546534B2 (ja) | 2014-07-09 |
| ZA201008274B (en) | 2012-02-29 |
| PL2510921T3 (pl) | 2017-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2725513C (en) | Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer | |
| Huang et al. | The landscape of mRNA nanomedicine | |
| JP7600208B2 (ja) | 拘束された脂質を含むナノ材料およびその使用 | |
| Hackett et al. | Fatty acids as therapeutic auxiliaries for oral and parenteral formulations | |
| ES2711669A1 (es) | Sistemas de liberacion de farmacos de acido polisialico y metodos | |
| CN116270534A (zh) | 一种组织选择性递送核酸药物的类脂质纳米颗粒及其制备方法和应用 | |
| WO2018096057A1 (en) | Particles comprising surfactant protein b and one or more lipids | |
| CN120303251A (zh) | 可电离脂质 | |
| KR20200072471A (ko) | 약학적 제제의 전달 조성물 및 방법 | |
| HK1159479B (en) | Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer | |
| HK1179533B (en) | Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer | |
| He et al. | Diverse nanoparticles deliver mRNA to enhance tumor immunotherapy | |
| CN117338948A (zh) | 一种ace2特异性结合肽修饰的递药系统及其制备方法和应用 | |
| CN117460537A (zh) | 核酸递送 | |
| EP4349328A1 (en) | Lipoprotein-mimicking solid lipid nanoparticles for drug delivery and uses thereof | |
| US20250275921A1 (en) | Composition for preventing or treating cancer, containing lipid nanoparticles | |
| Salunkhe et al. | Oral Delivery of Lipid Nanosystem: Pharmacokinetics and Pharmacodynamic Advances | |
| Huang | Functionalized Lipid Nanoparticles Show Efficacy in Glioma Animal Models | |
| EP4540392A1 (en) | Targeted nanomedicine for treating fibrotic lung disorders | |
| WO2025249511A1 (ja) | メッセンジャーｒｎａを腫瘍組織に導入するために用いられる組成物およびがん治療用医薬 | |
| TW202541786A (zh) | 脂質奈米顆粒 | |
| CN120531894A (zh) | 一种脂质纳米载体、药物制剂及制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |